Amgen (AMGN) Competitors

Amgen (NASDAQ:AMGN) and Gilead Sciences (NASDAQ:GILD) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, earnings, profitability, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and risk.

Is AMGN or GILD more profitable?

Gilead Sciences has a net margin of 20.76% compared to Amgen's net margin of 17.39%. Amgen's return on equity of 176.11% beat Gilead Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amgen	17.39%	176.11%	12.39%
Gilead Sciences	20.76%	51.93%	17.40%

Do analysts prefer AMGN or GILD?

Amgen currently has a consensus target price of $309.22, suggesting a potential upside of 13.50%. Gilead Sciences has a consensus target price of $110.55, suggesting a potential upside of 4.10%. Given Amgen's higher probable upside, equities research analysts plainly believe Amgen is more favorable than Gilead Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amgen	2 Sell rating(s)	12 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.38
Gilead Sciences	0 Sell rating(s)	9 Hold rating(s)	15 Buy rating(s)	3 Strong Buy rating(s)	2.78

Does the media prefer AMGN or GILD?

In the previous week, Amgen had 4 more articles in the media than Gilead Sciences. MarketBeat recorded 65 mentions for Amgen and 61 mentions for Gilead Sciences. Amgen's average media sentiment score of 1.51 beat Gilead Sciences' score of 1.14 indicating that Amgen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amgen	51 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Gilead Sciences	47 Very Positive mention(s)	2 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has stronger valuation and earnings, AMGN or GILD?

Amgen has higher revenue and earnings than Gilead Sciences. Gilead Sciences is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amgen	$33.42B	4.38	$4.09B	$10.96	24.86
Gilead Sciences	$28.75B	4.59	$480M	$4.75	22.36

Does the MarketBeat Community favor AMGN or GILD?

Gilead Sciences received 926 more outperform votes than Amgen when rated by MarketBeat users. Likewise, 76.84% of users gave Gilead Sciences an outperform vote while only 71.71% of users gave Amgen an outperform vote.

Company	Underperform	Outperform
Amgen	Outperform Votes 1559 71.71%	Underperform Votes 615 28.29%
Gilead Sciences	Outperform Votes 2485 76.84%	Underperform Votes 749 23.16%

Is AMGN or GILD a better dividend stock?

Amgen pays an annual dividend of $9.52 per share and has a dividend yield of 3.5%. Gilead Sciences pays an annual dividend of $3.16 per share and has a dividend yield of 3.0%. Amgen pays out 86.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Gilead Sciences pays out 66.5% of its earnings in the form of a dividend. Amgen has increased its dividend for 14 consecutive years and Gilead Sciences has increased its dividend for 10 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Which has more risk and volatility, AMGN or GILD?

Amgen has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.29, meaning that its share price is 71% less volatile than the S&P 500.

Do institutionals and insiders have more ownership in AMGN or GILD?

76.5% of Amgen shares are owned by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are owned by institutional investors. 0.7% of Amgen shares are owned by company insiders. Comparatively, 0.3% of Gilead Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Amgen beats Gilead Sciences on 12 of the 22 factors compared between the two stocks.